AR023542A1 - Pirazolbenzodiazepinas - Google Patents

Pirazolbenzodiazepinas

Info

Publication number
AR023542A1
AR023542A1 ARP000101817A ARP000101817A AR023542A1 AR 023542 A1 AR023542 A1 AR 023542A1 AR P000101817 A ARP000101817 A AR P000101817A AR P000101817 A ARP000101817 A AR P000101817A AR 023542 A1 AR023542 A1 AR 023542A1
Authority
AR
Argentina
Prior art keywords
pirazolbenzodiazepinas
pyrazolbenzodiazepines
cdfs
antiproliferatives
colon
Prior art date
Application number
ARP000101817A
Other languages
English (en)
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR023542A1 publication Critical patent/AR023542A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/22—Sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP000101817A 1999-04-21 2000-04-18 Pirazolbenzodiazepinas AR023542A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13037099P 1999-04-21 1999-04-21

Publications (1)

Publication Number Publication Date
AR023542A1 true AR023542A1 (es) 2002-09-04

Family

ID=22444382

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101817A AR023542A1 (es) 1999-04-21 2000-04-18 Pirazolbenzodiazepinas

Country Status (33)

Country Link
US (3) US6440959B1 (fr)
EP (1) EP1185529B1 (fr)
JP (1) JP3746680B2 (fr)
KR (1) KR100481757B1 (fr)
CN (2) CN1196703C (fr)
AR (1) AR023542A1 (fr)
AT (1) ATE279413T1 (fr)
AU (1) AU768667B2 (fr)
BR (1) BR0009887A (fr)
CA (1) CA2367704C (fr)
CO (1) CO5170444A1 (fr)
CZ (1) CZ20013738A3 (fr)
DE (1) DE60014893T2 (fr)
DK (1) DK1185529T3 (fr)
ES (1) ES2228522T3 (fr)
HK (1) HK1046278B (fr)
HR (1) HRP20010742A2 (fr)
HU (1) HUP0300318A3 (fr)
IL (1) IL145764A0 (fr)
JO (1) JO2248B1 (fr)
MA (1) MA26782A1 (fr)
NO (1) NO20015065D0 (fr)
NZ (1) NZ514523A (fr)
PE (1) PE20010054A1 (fr)
PL (1) PL200933B1 (fr)
PT (1) PT1185529E (fr)
RU (1) RU2249593C2 (fr)
SI (1) SI1185529T1 (fr)
TR (1) TR200103016T2 (fr)
TW (1) TW585866B (fr)
WO (1) WO2000064900A1 (fr)
YU (1) YU73101A (fr)
ZA (1) ZA200108016B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003041715A1 (fr) * 2001-11-13 2003-05-22 3-Dimensional Pharmaceuticals, Inc. 1,4-benzodiazepines substituees et leurs utilisations pour le traitement du cancer
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
JP2006519236A (ja) * 2003-02-27 2006-08-24 アボット・ラボラトリーズ 複素環式キナーゼ阻害剤
WO2006040036A1 (fr) * 2004-10-13 2006-04-20 F. Hoffmann-La Roche Ag Pyrazolobenzodiazepines disubstituees utiles en tant qu'inhibiteurs de cdk2 et de l'angiogenese, et destinees au traitement des cancers du sein, du colon, du poumon et de la prostate
KR20110010813A (ko) * 2005-10-14 2011-02-07 에프. 호프만-라 로슈 아게 5-(2-클로로페닐)-1,2-디히드로-7-플루오로-8-메톡시-3-메틸-피라졸로[3,4-ｂ][1,4] 벤조디아제핀의 투여 섭생
KR20150081370A (ko) 2006-07-10 2015-07-13 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
EP2305647A1 (fr) * 2009-09-18 2011-04-06 PAION UK Limited Procédé de préparation d'ester de méthyle d'acide 3-[(4S)-8-bromo-1-méthyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazépine-4-yl] propionique ou son sulfonate de benzène, et composants utiles dans ce procédé
EP2450039A1 (fr) 2010-11-08 2012-05-09 PAION UK Ltd. Régime de dosage permettant la sédation avec CNS 7056 (Remimazolam)
US9321737B2 (en) * 2012-02-02 2016-04-26 Senex Biotechnology Inc CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
CN103288830A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-5H-吡咯并[2,1-c][1,4]-苯并二氮杂卓的方法
CN103288828A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-6H-吲哚并[2,1-c][1,4]-苯并二氮杂卓的方法
CN102603743B (zh) * 2012-02-24 2014-05-28 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-（4-苯氧基）苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
EP3535253A1 (fr) * 2016-11-01 2019-09-11 H. Hoffnabb-La Roche Ag 1,3-dihydro -1,4-benzodiazépine-2-thiones pour le traitement de maladies liées au snc
EP3447056A4 (fr) * 2016-12-13 2019-09-18 Nanjing Transthera Biosciences Co. Ltd. Composé inhibiteur multi-kinase, forme cristalline et utilisation associée
CN109020980B (zh) * 2017-06-09 2020-11-20 华东师范大学 一类抗肿瘤作用的吡唑并嘧啶二氮*衍生物
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (fr) 2019-02-15 2020-08-20 Incyte Corporation Composés de pyrrolo[2,3-d]pyrimidinone en tant qu'inhibiteurs de cdk2
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223469A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
CR20220170A (es) 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
CA3182501A1 (fr) * 2020-05-08 2021-11-11 Transthera Sciences (Nanjing), Inc. Procede de synthese d'un compose antitumoral et d'un intermediaire de celui-ci
WO2022113003A1 (fr) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Inhibiteurs de cdk
WO2022149057A1 (fr) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Inhibiteurs de cdk
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
KR20240006610A (ko) * 2021-05-10 2024-01-15 트랜스테라 사이언시즈 (난징), 인크. 다중-키나제 억제제의 제약 조성물 및 용도
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024030399A2 (fr) * 2022-08-02 2024-02-08 Lab1636, Llc Utilisation d'un modulateur allostérique positif de gaba-a pour la réduction de l'hypersensibilité tactile

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2266519C (fr) 1996-10-02 2007-01-23 Novartis Ag Derives de pyrimidine et procedes de preparation de ces derniers
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers

Also Published As

Publication number Publication date
JP2002543081A (ja) 2002-12-17
CN1603314A (zh) 2005-04-06
CN1279029C (zh) 2006-10-11
HK1046278A1 (en) 2003-01-03
PL354405A1 (en) 2004-01-12
CN1196703C (zh) 2005-04-13
ES2228522T3 (es) 2005-04-16
HK1046278B (zh) 2005-08-12
CZ20013738A3 (cs) 2002-08-14
RU2249593C2 (ru) 2005-04-10
US6916923B2 (en) 2005-07-12
MA26782A1 (fr) 2004-12-20
PE20010054A1 (es) 2001-02-07
HUP0300318A2 (hu) 2003-06-28
US20040198976A1 (en) 2004-10-07
ATE279413T1 (de) 2004-10-15
AU768667B2 (en) 2003-12-18
TR200103016T2 (tr) 2002-04-22
WO2000064900A1 (fr) 2000-11-02
DE60014893T2 (de) 2005-10-13
US6440959B1 (en) 2002-08-27
JP3746680B2 (ja) 2006-02-15
KR20010112435A (ko) 2001-12-20
US20020183514A1 (en) 2002-12-05
NO20015065L (no) 2001-10-18
AU4748000A (en) 2000-11-10
TW585866B (en) 2004-05-01
US6838558B2 (en) 2005-01-04
DE60014893D1 (de) 2004-11-18
CN1348455A (zh) 2002-05-08
EP1185529B1 (fr) 2004-10-13
SI1185529T1 (en) 2005-02-28
PT1185529E (pt) 2005-02-28
NO20015065D0 (no) 2001-10-18
PL200933B1 (pl) 2009-02-27
KR100481757B1 (ko) 2005-04-11
HRP20010742A2 (en) 2002-12-31
CO5170444A1 (es) 2002-06-27
BR0009887A (pt) 2002-01-22
CA2367704A1 (fr) 2000-11-02
NZ514523A (en) 2003-11-28
HUP0300318A3 (en) 2004-11-29
DK1185529T3 (da) 2005-02-07
YU73101A (sh) 2004-05-12
ZA200108016B (en) 2003-03-26
CA2367704C (fr) 2008-06-17
JO2248B1 (en) 2004-10-07
EP1185529A1 (fr) 2002-03-13
IL145764A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
AR023542A1 (es) Pirazolbenzodiazepinas
PA8537401A1 (es) Diaminotiazoles
TR200003206T2 (tr) İndol türevleri ve patolojik hücre çoğalmasının neden olduğu habis hastalıklar ve diğer hastalıkların tedavisinde kullanımları.
BR9205811A (pt) Derivados heterociclicos de aminas ciclicas
BR9916327A (pt) Oxindóis de 4-alquenila (e alquinila) como inibidores de cinases dependentes de ciclina, em particular, cdk2
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
DE60112055D1 (de) Inhibitoren von gamma-secretase
BRPI0412348A (pt) derivados de piperazina e seu uso como agentes terapêuticos
PT1242060E (pt) Tratamento da doenca metastatica
ES2193508T3 (es) Ftalizinonas.
NO20005237D0 (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
NO20012567L (no) Azepinoindolderivater, fremstilling og anvendelse derav
PT998460E (pt) Novos derivados de tetrazole
PT889886E (pt) Novas fenantridinas substituidas na posicao 6
DE69106237D1 (de) Antimigräne Alkoxypyrimidinderivate.
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
ES2101858T3 (es) Derivados de geneserina como inhibidores de colinesterasa.
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
BR9813719A (pt) Agentes terapêuticos
BR9916216A (pt) 4.5-azolo-oxindóis
ECSP003445A (es) Pirazolbenzodiazepinas
UY26498A1 (es) Pirroles sustituidos
ES2154370T3 (es) Alquenil-benzoilguanidinas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal